New Drugs in Cancer Therapy, National Tumor Institute, Naples, 17-18 June 2004

Anti-Cancer Drugs

Volumn 16, Issue 2, 2005, Pages 211-221

  Caponigro, Francesco ^a   Basile, Maria ^a   De Rosa, Vincenzo ^a   Normanno, Nicola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Angiogenesis; Cancer therapy; Epidermal growth factor receptor; New drugs; Signal transduction

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; BBR 3464; BEVACIZUMAB; CETUXIMAB; DEPSIPEPTIDE; DIFLOMOTECAN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; IDARUBICIN; IMATINIB; IXABEPILONE; MATUZUMAB; MONOCLONAL ANTIBODY; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NEW DRUG; PANITUMUMAB; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; ROSCOVITINE; SABARUBICIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VORINOSTAT;

AGITATION; ALOPECIA; ANEMIA; ANESTHESIA (SENSORY DYSFUNCTION); ANOREXIA; ATAXIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST METASTASIS; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CONFUSION; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG TARGETING; DYSPNEA; FATIGUE; FEVER; GAIT DISORDER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; ITALY; KIDNEY CARCINOMA; KIDNEY DISEASE; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROTEINURIA; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOSIS; VERTIGO; VOMITING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; GENES, ERBB; NEOPLASMS; PIPERAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 13844271999     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200502000-00014     Document Type: Conference Paper

References (61)

1. Zhuang SH, Menefee M, Kotz H, et al. A phase II clinical trial of BMS-247550, a microtubule stabilizing agent in renal cell cancer. Proc Am Soc Clin Oncol 2004; 23:393a (abstr 4550).
2. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3:502-516.
3. Sternberg CN, Hetherington J, Paluchowska B, et al. Randomized phase III trial of a novel oral platinum, Satraplatin (JM-216) plus prednisone or prednisone alone in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2003; 22:395a (abstr 1586).
4. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drug 1997; 54:15-21.
5. O'Brien ME, Wigler N, lnbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX/ Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15:440-449.
6. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-3322.
7. Arcamone F, Animati F, Berettone M, et al. Doxorubicin disaccaride analogue: apoptosis-related improvement of efficacy in vivo. J Natl Cancer Inst 1997; 89:1217-1223.
8. Schrijvers D, Bos AME, Dyck J, et al. Phase I study of MEN 10-755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group. Ann Oncol 2002; 13:385-391.
9. Roelvink M, Aamdal S, Dombernowsky P, et al. Phase I study of MEN 10-755 in patients with a solid tumor as a short i.v. infusion given once every 3 weeks. Eur J Cancer 1999; 35(suppl 4):289.
10. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-2799.
11. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
12. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1458-1461.
13. Normanno N, Campigli M, De Luca A, et al. Cooperative inhibitory effect of ZD1839 (lressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002; 13:65-72.
14. Albain KS, Elledge R, Gradishar WJ, et al. Open label, phase II, multicenter trial of ZD1839 (lressa) in patients with advanced breast cancer. Breast Cancer Res Treat 2002; 76:333 (abstr).
15. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Il trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2227-2229.
16. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Ass 2003; 290:2148-2158.
17. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 2004; 351:337-345.
18. Burtness BA, Li Y, Flood W, et al. Phase III trial comparing cisplatin + placebo to cisplatin + anti-epidermal growth factor antibody (EGF-R) C225 in patients with metastatic/recurrent head & neck cancer. Proc Am Soc Clin Oncol 2002; 21:226a (abstr 901).
19. Bonner JA, Giralt J, Harari PM, et al. Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 2004; 23:17a (abstr 5507).
20. Robert F, Blumenschei G, Dicke K, et al. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:643a (abstr 2587).
21. Kelly K, Hanna N, Rosemberg A, et al. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:645a (abstr 2592).
22. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) versus CV alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2004; 23:618a (abstr 7012).
23. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD 72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22:175-184.
24. Trarbach T, Beyer T, Schleucher N, et al. A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. Proc Am Soc Clin Oncol 2004; 23:199a (abstr 3018).
25. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003-3015.
26. Hecht JR, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004; 23:248a (abstr 3511).
27. Cobleigh MA, Vogel CL, Tripathy D, et al. multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
28. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001; 344:783-792.
29. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726.
30. Emens LA, Davidson NE. Trastuzumab in breast cancer. Oncology 2004; 18:1117-1128.
31. Comelia G, D'Aiuto G, Cornelia P, et al. Comparison of weekly cisplatin-epirubicin-paclitaxel (PET) with triweekly epirubicin-paclitaxel (ET) in I ocally advanced breast cancer. Proc Am Soc Clin Oncol 2004; 23:5a (abstr 511).
32. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421-1423.
33. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480.
34. Garofalo A, Naumova E, Manenti L, et al. The combination of the tyrosine kinase inhibitor SU 6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 2003; 9:3476-3485.
35. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20:3792-3803.
36. Eder JP, Supko JG, Clark JW, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002; 20:3772-3784.
37. Hansma AHG, Hoeckman K, Broxterman HJ, et al. A phase I study of RhEndostatin: continuous intravenous followed by subcutaneous administration. Proc Am Soc Clin Oncol 2002; 21:110a (abstr 436).
38. Hanna NH, Estes D, Cress A, Sidor C. Recombinant human angiostatin in combination with paclitaxel and carboplatin in patients with advanced NSCLC: preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2004; 23:7105a (abstr 639).
39. Bhargava P, Marshall JL, Rizvi N, et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999; 5:1989-1995.
40. Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001; 7:1198-1203.
41. Stadler WM, Kuzel T, Shapiro C, et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999; 17:2541-2545.
42. Kuemen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU 5416 in patients with solid tumors. J Clin Oncol 2002; 20:1657-1667.
43. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. W Engl J Med 2003; 349:427-434.
44. Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncology 2004; 9(suppl 1):43-49.
45. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
46. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effect of ZD 6474 a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9:1546-1556.
47. Heymach JV, Dong RP, Dimeri I, et al. ZD 6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: results of the run in phase of a two-part, randomized phase II study. Proc Am Soc Clin Oncol 2004; 23:3051a (abstr 207).
48. Trarbach T, Thomas AL, Bartel C, et al. Preliminary phase I results of the oral, once daily angiogenesis inhibitor PTK787/ZK222584 (PTK/ZK) in combination with chemotherapy for the treatment of metastatic colorectal cancer. Eur J Cancer 2003; 1:297 (S91 abstr).
49. George D, Michaelson D, Oh WK, et al. Phase I study of PTK787/ ZK222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003; 22:385a (abstr 1548).
50. Caponigro F, Casale M, Bryce J. Farnesyl transferase inhibitors in clinical development. Curr Opin Invest Drugs 2003; 12:943-954.
51. Theodore C, Geoffrois L, Vermerken JB, et al. A phase II multicentre study of SCH 66336 in combination with gemcitabine as second line treatment in patients with advanced/metastatic urothelial tract tumor. Proc Am Soc Clin Oncol 2003; 22:415a (abstr 1667).
52. Rao S, Cunningham D, de Gramont A, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004; 22:3950-3957.
53. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22:1430-1438.
54. Benson C, White J, Twelves C, et al. A phase I trial of the oral cyclin-dependent kinase inhibitor CYC202 in patients with advanced malignancy. Proc Am Soc Clin Oncol 2003; 22:209a (abstr 838).
55. Pierga JY, Faivre S, Vera K, et al. A phase I and pharmacokinetic trial of CYC202, a novel oral cyclin-dependent kinase inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2003; 22:210a (abstr 840).
56. Jones SF, Burris HA, Kies M, et al. A phase I study to determine the safety and pharmacokinetics of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. Proc Am Soc Clin Oncol 2003; 22:199a (abstr 798).
57. Shapiro G, Lewis N, Bai S, et al. A phase I study to determine the safety and pharmacokinetics of BMS-387032 with a 24-hour infusion given every three weeks in patients with metastatic refractory solid tumors. Proc Am Soc Clin Oncol 2003; 22:199a (abstr 799).
58. McCormick J, Gadgeel SM, Helmke W, et al. Phase I study of BMS-387032, a cyclin dependent kinase (CDK) 2 inhibitor. Proc Am Soc Clin Oncol 2003; 22:208a (abstr 835).
59. Piekarz R, Robey R, Fojo T, et al. Analysis of molecular markers and targets in trials of depsipeptide, FR901228, a histone deacetylase inhibitor with clinical activity in T-cell lymphoma. Proc Am Soc Clin Oncol 2002; 21:23a (abstr 88).
60. Piekarz R, Frye R, Turner M, et al. Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Proc Am Soc Clin Oncol 2004; 23:202a (abstr 3028).
61. Bruzzese F, Di Gennaro E, Budillon A. Synergistic antitumor effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in combination with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) in squamous-cell carcinoma of the head and neck derived cell lines. Proc Am Ass Cancer Res 2004; 95:1299a (abstr 5625).